AMEX:VNRX

Stock Analysis Report

Executive Summary

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide.

Snowflake

Fundamentals

Adequate balance sheet with moderate growth potential.

Risks

  • VolitionRx has significant price volatility in the past 3 months.

Share Price & News

How has VolitionRx's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

6.8%

AMEX:VNRX

0.5%

US Medical Equipment

-0.02%

US Market


1 Year Return

86.8%

AMEX:VNRX

9.9%

US Medical Equipment

1.6%

US Market

VNRX outperformed the Medical Equipment industry which returned 9.7% over the past year.

VNRX outperformed the Market in United States of America which returned 1.9% over the past year.


Share holder returns

VNRXIndustryMarket
7 Day6.8%0.5%-0.02%
30 Day3.9%0.09%2.7%
90 Day36.5%2.0%1.4%
1 Year86.8%86.8%10.8%9.9%3.8%1.6%
3 Year-12.7%-12.7%69.0%63.9%45.2%35.8%
5 Year0.2%0.2%136.2%109.3%61.8%44.1%

Price Volatility Vs. Market

How volatile is VolitionRx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is VolitionRx undervalued based on future cash flows and its price relative to the stock market?

10.27x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for VolitionRx to establish if it is available at moderate discount.

Unable to calculate intrinsic value for VolitionRx to establish if it is available at substantial discount.


Price Based on Earnings

VolitionRx is loss making, we can't compare its value to the US Medical Equipment industry average.

VolitionRx is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for VolitionRx, we can't assess if its growth is good value.


Price Based on Value of Assets

VolitionRx is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is VolitionRx expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

61.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if VolitionRx is high growth as no revenue estimate data is available.

VolitionRx's earnings are expected to grow significantly at over 20% yearly.

Unable to compare VolitionRx's revenue growth to the United States of America market average as no estimate data is available.

VolitionRx's earnings growth is expected to exceed the United States of America market average.

VolitionRx's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if VolitionRx will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has VolitionRx performed over the past 5 years?

-20.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

VolitionRx does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare VolitionRx's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare VolitionRx's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if VolitionRx has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if VolitionRx has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if VolitionRx improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is VolitionRx's financial position?


Financial Position Analysis

VolitionRx is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

VolitionRx's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

VolitionRx's level of debt (15.4%) compared to net worth is satisfactory (less than 40%).

Unable to establish if VolitionRx's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 7.6x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

VolitionRx has sufficient cash runway for 1.2 years based on current free cash flow.

Unable to confirm if VolitionRx has at least 1 year of cash runway based on growing free cash flows without relevant data.


Next Steps

Dividend

What is VolitionRx's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate VolitionRx's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate VolitionRx's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as VolitionRx has not reported any payouts.

Unable to verify if VolitionRx's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as VolitionRx has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of VolitionRx's salary, the management and board of directors tenure and is there insider trading?

4.3yrs

Average management tenure


CEO

Cameron Reynolds (48yo)

7.9yrs

Tenure

US$567,885

Compensation

Mr. Cameron Reynolds, MBA has been the President and Group Chief Executive Officer of VolitionRX Ltd since October 6, 2011. He founded VolitionRX in 2010. Mr. Reynolds has been the Chief Executive Officer  ...


CEO Compensation Analysis

Insufficient data for Cameron to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.

Cameron's compensation has increased whilst company is loss making.


Management Age and Tenure

4.3yrs

Average Tenure

49.5yo

Average Age

The tenure for the VolitionRx management team is about average.


Board Age and Tenure

7.9yrs

Average Tenure

52.5yo

Average Age

The tenure for the VolitionRx board of directors is about average.


Insider Trading

More shares have been bought than sold by VolitionRx individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$37,50028 Aug 19
Martin Faulkes
EntityIndividual
Role
Chairman of the Board
Executive Chairman
Shares10,000
Max PriceUS$3.75
BuyUS$197,00016 Aug 19
Martin Faulkes
EntityIndividual
Role
Chairman of the Board
Executive Chairman
Shares50,000
Max PriceUS$3.94
BuyUS$1,274,84001 Aug 19
Cotterford Company Limited
EntityCompany
Shares450,110
Max PriceUS$2.93
SellUS$1,274,84001 Aug 19
Hever Investments Limited
EntityCompany
Shares450,110
Max PriceUS$2.93
BuyUS$251,64801 Aug 19
Cotterford Company Limited
EntityCompany
Shares86,419
Max PriceUS$2.95
BuyUS$246,13413 Jun 19
Martin Faulkes
EntityIndividual
Role
Chairman of the Board
Executive Chairman
Shares79,269
Max PriceUS$3.14
BuyUS$213,60812 Jun 19
Martin Faulkes
EntityIndividual
Role
Chairman of the Board
Executive Chairman
Shares70,731
Max PriceUS$3.02

Ownership Breakdown


Management Team

  • Cameron Reynolds (48yo)

    Founder

    • Tenure: 7.9yrs
    • Compensation: US$567.89k
  • Rod Rootsaert (48yo)

    Corporate Secretary

    • Tenure: 7.9yrs
    • Compensation: US$262.72k
  • Dill Faulkes (75yo)

    Executive Chairman

    • Tenure: 8.5yrs
    • Compensation: US$289.76k
  • Jake Micallef (63yo)

    Chief Scientific Officer

    • Tenure: 4.7yrs
    • Compensation: US$411.73k
  • Jason Terrell (39yo)

    Chief Medical Officer

    • Tenure: 0yrs
    • Compensation: US$231.16k
  • Tom Bygott

    Sales & Marketing Director

    • Tenure: 0yrs
  • Gaetan Michel

    Chief Executive Officer of Belgian Volition SPRL

    • Tenure: 4yrs
  • Louise Batchelor Day

    Chief Marketing & Communications Officer

    • Tenure: 3.4yrs
  • Scott Powell

    Executive Vice President of Investor Relations

    • Tenure: 0yrs
  • David Vanston (51yo)

    Group CFO & Treasurer

    • Tenure: 2.4yrs

Board Members

  • Guy Innes (63yo)

    Lead Independent Director

    • Tenure: 0yrs
    • Compensation: US$102.86k
  • Cameron Reynolds (48yo)

    Founder

    • Tenure: 7.9yrs
    • Compensation: US$567.89k
  • Habib Skaff (42yo)

    Non-Executive Director

    • Tenure: 5.3yrs
    • Compensation: US$72.96k
  • Robert Weinzierl (57yo)

    Member of Scientific Advisory Board

    • Tenure: 7.9yrs
  • Dill Faulkes (75yo)

    Executive Chairman

    • Tenure: 8.5yrs
    • Compensation: US$289.76k
  • Andreas Ladurner (48yo)

    Member of Scientific Advisory Board

    • Tenure: 7.9yrs
  • Sarah Lee (43yo)

    Secretary of Hypergenomics Pte Limited and Director of Hypergenomics Pte Limited

    • Tenure: 0yrs
    • Compensation: US$90.84k
  • Alan Colman (70yo)

    Chairman of Scientific Advisory Board & Independent Non Executive Director

    • Tenure: 7.9yrs
    • Compensation: US$100.27k
  • Roland Andersson

    Member of Scientific Advisory Board

    • Tenure: 4.2yrs
  • Jorge Reis-Filho

    Member of Scientific Advisory Board

    • Tenure: 4.2yrs

Company Information

VolitionRx Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: VolitionRx Limited
  • Ticker: VNRX
  • Exchange: AMEX
  • Founded:
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$175.043m
  • Shares outstanding: 41.09m
  • Website: https://volitionrx.com

Number of Employees


Location

  • VolitionRx Limited
  • No. 24-05 Shaw Centre
  • 1 Scotts Road
  • Singapore
  • 228208
  • Singapore

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VNRXAMEX (NYSE MKT LLC)YesCommon StockUSUSDOct 2011

Biography

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays t ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/19 00:24
End of Day Share Price2019/09/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.